Invitrogen™ CD254 (RANK Ligand) Monoclonal Antibody (IK22/5), Functional Grade, eBioscience™, Invitrogen™

Description

The IK22/5 MAb reacts with mouse CD254 also known as TRANCE (TNF-related activation-induced cytokine receptor) and RANKL (receptor activator of NF-kappa B ligand) and OPGL (Osteoprotegerin Ligand). TRANCE is a type II membrane protein with predicted molecular weight of 35 kDa. Its extracellular domain is most closely related to TRAIL, FasL and TNF. TRANCE mRNA is upregulated by TCR stimulation and is expressed abundantly by mouse T cells not B cells in mouse thymus and lymph nodes. TRANCE-deficient mouse lacks osteoclasts. In addition, TRANCE has been shown to be involved in the interactions between T-dendritic and T-B cells. It was also found to be critical in osteoclast differentiation. The TRANCE-RANK interaction regulates the expression of the anti-apoptotic molecule Bcl-xL.

This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.